ECSP045242A - Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea - Google Patents

Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea

Info

Publication number
ECSP045242A
ECSP045242A EC2004005242A ECSP045242A ECSP045242A EC SP045242 A ECSP045242 A EC SP045242A EC 2004005242 A EC2004005242 A EC 2004005242A EC SP045242 A ECSP045242 A EC SP045242A EC SP045242 A ECSP045242 A EC SP045242A
Authority
EC
Ecuador
Prior art keywords
ambroxol
oral
treatment
painful conditions
pharyngeal cavity
Prior art date
Application number
EC2004005242A
Other languages
English (en)
Spanish (es)
Inventor
Anke Esperester
Uwe Pschorn
Jean-Michael Vix
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27740434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045242(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP045242A publication Critical patent/ECSP045242A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EC2004005242A 2002-02-27 2004-08-20 Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea ECSP045242A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10208313A DE10208313A1 (de) 2002-02-27 2002-02-27 Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum

Publications (1)

Publication Number Publication Date
ECSP045242A true ECSP045242A (es) 2004-09-28

Family

ID=27740434

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005242A ECSP045242A (es) 2002-02-27 2004-08-20 Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea

Country Status (21)

Country Link
EP (1) EP1480626A1 (de)
JP (1) JP2005518435A (de)
KR (1) KR20040084944A (de)
CN (1) CN1638749A (de)
AR (1) AR038698A1 (de)
AU (1) AU2003210345B2 (de)
BR (1) BR0308038A (de)
CA (1) CA2477105A1 (de)
DE (1) DE10208313A1 (de)
EC (1) ECSP045242A (de)
IS (1) IS7417A (de)
MX (1) MXPA04008220A (de)
MY (1) MY144781A (de)
PE (1) PE20030830A1 (de)
PL (1) PL371584A1 (de)
RU (1) RU2311176C2 (de)
TW (1) TW200306804A (de)
UA (1) UA86741C2 (de)
UY (1) UY27679A1 (de)
WO (1) WO2003072094A1 (de)
ZA (1) ZA200405635B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10332486A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung akuter Schmerzen
JP2005120063A (ja) * 2003-10-14 2005-05-12 Boehringer Ingelheim Pharma Gmbh & Co Kg 咽頭における炎症の治療のためのアンブロキソール
ITMI20032462A1 (it) * 2003-12-16 2005-06-17 Advance Holdings Ltd Metodo per preparare una caramella contenente ambroxolo e la caramella cosi' ottenuta
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
JP2007084471A (ja) * 2005-09-21 2007-04-05 Sunstar Inc 口腔用組成物および口腔用製品の選択方法
EP2015761A4 (de) * 2006-03-29 2009-07-29 Naveh Pharma 1996 Ltd Verfahren und zusammensetzung zur behandlung von halsentzündung
JP5765934B2 (ja) * 2009-12-28 2015-08-19 サンスター株式会社 口腔用組成物
JP6171683B2 (ja) * 2012-08-03 2017-08-02 大正製薬株式会社 固形製剤
CN105769908B (zh) * 2016-05-06 2019-03-01 湖北凤凰白云山药业有限公司 一种化痰止咳的药物及其制备方法
WO2018089797A1 (en) 2016-11-14 2018-05-17 Mingwu Wang Formulations for the treatment of ocular surface diseases and related methods
CN106727621A (zh) * 2016-11-22 2017-05-31 郑州仁宏医药科技有限公司 一种治疗牙痛的西药散剂
JP6844394B2 (ja) * 2017-04-14 2021-03-17 大正製薬株式会社 固形組成物
EP3415143A1 (de) 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexin zur behandlung von schmerz

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138020B1 (de) * 1983-09-17 1992-06-03 Dr. Karl Thomae GmbH Antiadhäsive Prophylactica und Arzneimittel enthaltend ein sekretolytisch wirksames Benzylaminderivat
DE3445226A1 (de) * 1983-12-14 1985-08-01 Reifenrath, Rainer Richard Otto, Dr.med., 7920 Heidenheim Pharmazeutisches erzeugnis zur behandlung und prophylaxe von infektionen sowie von husten und obstruktiven atemwegserkrankungen
US5122540A (en) * 1986-02-28 1992-06-16 W. Keith R. Watson Method and composition for treating warts and throat soreness with DMSO and citric acid
DE4415553A1 (de) * 1994-05-03 1995-11-09 Behringwerke Ag Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
WO1997041832A1 (fr) * 1996-05-02 1997-11-13 Taisho Pharmaceutical Co., Ltd. Suspension de medicament acide difficilement soluble dans l'eau
DE19933148A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette
JP2001151677A (ja) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物
DE20102817U1 (de) * 2000-02-23 2001-06-07 Bolder Arzneimittel GmbH, 50968 Köln Lutsch- und Kaupastillen mit Cyclodextrin
US6391886B1 (en) * 2000-12-04 2002-05-21 The Procter & Gamble Company Oral compositions having improved consumer aesthetics

Also Published As

Publication number Publication date
RU2311176C2 (ru) 2007-11-27
AU2003210345B2 (en) 2009-01-29
AR038698A1 (es) 2005-01-26
EP1480626A1 (de) 2004-12-01
JP2005518435A (ja) 2005-06-23
CA2477105A1 (en) 2003-09-04
MY144781A (en) 2011-11-15
TW200306804A (en) 2003-12-01
PE20030830A1 (es) 2003-10-31
UY27679A1 (es) 2003-09-30
WO2003072094A1 (de) 2003-09-04
AU2003210345A1 (en) 2003-09-09
MXPA04008220A (es) 2004-11-26
PL371584A1 (en) 2005-06-27
RU2004129284A (ru) 2005-06-10
UA86741C2 (ru) 2009-05-25
CN1638749A (zh) 2005-07-13
DE10208313A1 (de) 2003-09-11
BR0308038A (pt) 2004-12-28
IS7417A (is) 2004-08-19
KR20040084944A (ko) 2004-10-06
ZA200405635B (en) 2005-05-31

Similar Documents

Publication Publication Date Title
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
ECSP045242A (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
FR2878159B1 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
ECSP077843A (es) Tratamiento o prevención del prurito
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
BRPI0409175A (pt) preparação farmacêutica oral para antagonistas de bombeamento de próton
PA8800601A1 (es) Productos quimioterapeuticos cristalinos
PA8800401A1 (es) Productos quimioterapeuticos cristalinos
AR077451A1 (es) Utilizacion de benzidamina en el tratamiento de enfermedades dependientes de p40
GT200300020A (es) Polimorfismos geneticos en el gen de la preprotaquiquinina
GT200200002A (es) Utilizacion de cromanos
GT200500267A (es) Uso de epotilonas en el tratamiento de metastasis en hueso
BRPI0412681A (pt) composição farmacêutica para a administração por via nasal de piribedil
UY28771A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis.
UY29303A1 (es) Medicamentos para el tratamiento o la prevencion de enfermedades fibroticas
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.